The Occurrence of rtA194T Mutant After Long-Term Lamivudine Monotherapy Remains Sensitive to Tenofovir Disoproxil Fumarate: A Case Report

References

• Ganem D, Prince AM. Hepatitis B virus infection–natural history and clinical consequences. N Engl J Med. 2004;350(11):1118–1129. doi:10.1056/NEJMra03108715014185
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–1599.29405329
   PubMed Web of Science ®Google Scholar
• Fung S, Kwan P, Fabri M, et al. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2014;146(4):980–988. doi:10.1053/j.gastro.2013.12.02824368224
   PubMed Web of Science ®Google Scholar
• Kabbara WK, Ramadan WH. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults. J Infect Public Health. 2015;8(5):409–417. doi:10.1016/j.jiph.2015.04.02026001757
   PubMed Web of Science ®Google Scholar
• Behrens G, Rijnders B, Nelson M, et al. Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis. AIDS Patient Care STDS. 2014;28(4):168–175. doi:10.1089/apc.2013.031024660840
   PubMed Web of Science ®Google Scholar
• Liu Y, Corsa AC, Buti M, et al. No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment. J Viral Hepat. 2017;24(1):68–74. doi:10.1111/jvh.1261327658343
   PubMed Web of Science ®Google Scholar
• Sheldon J, Camino N, Rodés B, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther (Lond). 2005;10:727–734.
   PubMed Web of Science ®Google Scholar
• Amini-Bavil-Olyaee S, Herbers U, Sheldon J, Luedde T, Trautwein C, Tacke F. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology. 2009;49(4):1158–1165. doi:10.1002/hep.2279019263474
   PubMed Web of Science ®Google Scholar
• Delaney WE, Ray AS, Yang H, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother. 2006;50(7):2471–2477. doi:10.1128/AAC.00138-0616801428
   PubMed Web of Science ®Google Scholar
• Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2(3):263–283. doi:10.1007/s12072-008-9080-319669255
   PubMed Web of Science ®Google Scholar
• Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology. 2000;119(1):172–180. doi:10.1053/gast.2000.855910889166
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003;124(1):105–117. doi:10.1053/gast.2003.5001312512035
   PubMed Web of Science ®Google Scholar
• Zoulim F, Locarnini S. Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance. Liver Int. 2013;33(Suppl 1):116–124. doi:10.1111/liv.1206923286855
   PubMed Web of Science ®Google Scholar
• Dupouey J, Gerolami R, Solas C, Colson P. Hepatitis B virus variant with the a194t substitution within reverse transcriptase before and under adefovir and tenofovir therapy. Clin Res Hepatol Gastroenterol. 2012;36(2):e26–e28. doi:10.1016/j.clinre.2012.01.00322342116
   PubMed Web of Science ®Google Scholar
• Dos Santos M, Pacheco SR, Stocker A, et al. Mutations associated with drug resistance and prevalence of vaccine escape mutations in patients with chronic hepatitis B infection. J Med Virol. 2017;89(10):1811–1816. doi:10.1002/jmv.2485328500726
   PubMed Web of Science ®Google Scholar
• Pastor R, Habersetzer F, Fafi-Kremer S, et al. Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naive patients. World J Gastroenterol. 2009;15(6):753–755. doi:10.3748/wjg.15.75319222103
   PubMed Web of Science ®Google Scholar
• Alvarado-Esquivel C, de la Ascensión Carrera-gracia M, Conde-González CJ, et al. Genotypic resistance to lamivudine among hepatitis B virus isolates in Mexico. J Antimicrob Chemother. 2006;57(2):221–223. doi:10.1093/jac/dki45716373428
   PubMed Web of Science ®Google Scholar
• Chu CJ, Keeffe EB, Han SH, et al. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology. 2003;125(2):444–451. doi:10.1016/S0016-5085(03)00895-312891547
   PubMed Web of Science ®Google Scholar
• Chu CJ, Keeffe EB, Han SH, et al. Prevalence of HBV precore/core promoter variants in the United States. Hepatology. 2003;38(3):619–628. doi:10.1053/jhep.2003.5035212939588
   PubMed Web of Science ®Google Scholar
• Yin J, Xie J, Liu S, et al. Association between the various mutations in viral core promoter region to different stages of hepatitis B, ranging of asymptomatic carrier state to hepatocellular carcinoma. Am J Gastroenterol. 2011;106(1):81–92. doi:10.1038/ajg.2010.39920959817
   PubMed Web of Science ®Google Scholar
• Erlinger S, Arias IM, Dhumeaux D. Inherited disorders of bilirubin transport and conjugation: new insights into molecular mechanisms and consequences. Gastroenterology. 2014;146(7):1625–1638. doi:10.1053/j.gastro.2014.03.04724704527
   PubMed Web of Science ®Google Scholar
• Strassburg CP. Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome). Best Pract Res Clin Gastroenterol. 2010;24(5):555–571. doi:10.1016/j.bpg.2010.07.00720955959
   PubMed Web of Science ®Google Scholar
• Thoguluva Chandrasekar V, John S. Gilbert Syndrome. StatPearls; 2021.
   Google Scholar
• Rotger M, Taffe P, Bleiber G, et al. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis. 2005;192(8):1381–1386. doi:10.1086/46653116170755
   PubMed Web of Science ®Google Scholar
• Korenblat KM, Berk PD. Hyperbilirubinemia in the setting of antiviral therapy. Clin Gastroenterol Hepatol. 2005;3(4):303–310. doi:10.1016/S1542-3565(05)00083-215822033
   PubMed Web of Science ®Google Scholar